RPG Life Sciences · NSE: RPGLIFE · BSE: 532983
Q4 FY21 results · Jan–Mar 2021
RPG Life Sciences reported revenue from operations of ₹92.76 crore (up 4.6% from Q4 FY20) and net profit of ₹6.92 crore (up 132.2% from Q4 FY20) for Q4 FY21 (Jan–Mar 2021), on a standalone basis.
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 92.76 | 88.67 | +4.6% | 107.60 | −13.8% |
| Other income | 0.30 | 0.38 | −21.1% | 0.12 | +150.0% |
| Total income | 93.06 | 89.05 | +4.5% | 107.72 | −13.6% |
| Profit before tax | 8.95 | 3.14 | +185.0% | 17.07 | −47.6% |
| Net profit for the period | 6.92 | 2.98 | +132.2% | 12.87 | −46.2% |
| EPS, basic (₹) | 4.18 | 1.80 | +132.2% | 7.78 | −46.3% |
| Net margin (%) | 7.5 | 3.4 | 12.0 |
Standalone
- Filed with BSE
- 04 May 2021, 14:41 IST
- Board meeting
- 30 Apr 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE